About
About D. Western Therapeutics Institute, Inc
D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. It offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining. The company is also developing DW-5LBT, a lidocaine patch for neuropathic pain after shingles; and DWR-2206, a regenerative medicine cell-product for bullous keratopathy. D. Western Therapeutics Institute, Inc. was founded in 1999 and is headquartered in Nagoya, Japan.
Visit company website
5 years, 6 months ago
D. Western Therapeutics Institute, Inc is currently in a long term downtrend where the price is trading 8.9% below its 200 day moving average.
From a valuation standpoint, the stock is 64.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 24.8.
D. Western Therapeutics Institute, Inc's total revenue sank by 10.6% to $115M since the same quarter in the previous year.
Its net income has dropped by 1044.3% to $-125M since the same quarter in the previous year.
Based on the above factors, D. Western Therapeutics Institute, Inc gets an overall score of 1/5.